AZN logo
AstraZeneca PLC
AZN
89.10 (0.72%) 0.64
Health Care
Pharmaceuticals
AstraZeneca PLC a biopharmaceutical company focuses on the discovery development manufacture and commercialization of prescription medicines. The company offers Imjudo Datroway Iressa Tagrisso Imfinzi Lynparza Calquence Enhertu Orpathys Truqap Zoladex Faslodex Farxiga Brilinta Crestor Seloken Lokelma Roxadustat Andexxa Wainua Symbicort Fasenra Pulmicort Breztri/Trixeo Saphnelo Tezspire Airsupra Ultomiris Soliris Strensiq Koselugo Kanuma Atacand Plendil Modip Splendil Munobal Flodil Komboglyze Qtern Byetta XIGDUO Accolate Accoleit Vanticon Beyfortus Synagis FluMist tixagevimab and cilgavimab and sipavibart. It also provides Bricanyl Respules Eklira Genuair/Tudorza/Bretaris Bricanyl Turbuhaler Rhinocort Bevespi Aerosphere Daliresp/Daxas Oxis Turbuhaler Breztri Aerosphere Duaklir Genuair Kavigale Evusheld Fluenz/FluMist and Voydeya. The company offers its products for ocology cardiovascular renal and metabolism respiratory & immunology vaccines and immune and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom the United States Europe and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare life sciences and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates with the potential to treat diseases across multiple indications; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge the United Kingdom.

Quality Checklist 5/8

ROIC > 10%
Debt/Equity < 1
Net Margin > 10%
Past Net Income CAGR > 0%
Est. EPS Growth > 5%
5Y Shares Out Change < 0%
Current Ratio > 1
Quick Ratio > 1
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $276.21(B)
EV: $300.27(B)
Total Equity: $45.97(B)
Earnings date: Feb-10-2026
P/E: 29.39
Forward P/E: 19.32
P/FCF: 21.83
P/S: 4.75
P/B: 6.02
EPS: $3.0
EPS (fwd): $4.6
FCF/share: $4.1
Revenue/share: $18.8
Book value/share: $14.8
ROIC: 12.5%
ROA: 8.6%
ROE: 21.7%
Debt/Equity: 0.71
Current Ratio: 0.90
Gross margin: 83.3%
Operating margin: 22.0%
Net margin: 16.2%
Dividend/share: $1.6
Div. yield: 1.76%

AZN Valuation & Price Targets

Current Price
$89.1

Favorite Valuation Methods

More Valuation Methods

DCF (simple)
N/A
N/A
DCF (exit mult.)
N/A
N/A
DDM
N/A
N/A
EPS growth
N/A
N/A
Revenue growth
N/A
N/A
Peter Lynch FV
N/A
N/A
Graham No.
N/A
N/A

PEvaluation

46% overvalued
Low
$36.1
Mid
$48.1
High
$60.1
Current price
$89.1
Fair P/E
Margin of safety
EPS
Market Model
Shares outstan...ROICRevenue growthDebt/FCFAssets/Liabili...
Economic moat: None/narrow

EPS Estimates

LowAvgHigh#
FY+14.54.64.718
FY+25.05.25.718
FY+35.35.96.517
FY+45.56.47.29
FY+55.67.28.28

Analyst Price Targets

N/A
No analyst price targets

Analyst Recommendations

Strong Buy4
Buy16
Hold1
Sell1
Strong Sell0

2-stage DCF

First Stage Duration: 5 Years
Starting Free Cash Flow
First Stage Growth Rate
LowMidHigh
Terminal Growth Rate
LowMidHigh
Discount Rate

Discounted Cash Flow

Forecast years: 5 Years
Terminal Growth Rate
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Discounted Cash Flow (exit mult.)

Forecast years: 5 Years
Exit FCF Multiple
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Dividend Discount Model

Annual Dividend
First Stage Length (Years): 0 Years
First Stage Growth Rate
Final Growth Rate
Discount Rate

EPS Growth

Forecast years: 5 Years
Starting EPS
EPS Growth Rate
LowMidHigh
Final P/E
LowMidHigh
Discount Rate

Revenue Growth Valuation

Forecast Years: 10 Years
Base Revenue
Revenue Growth Rate
LowMidHigh
Final Net Margin
LowMidHigh
Final P/E Ratio
LowMidHigh
Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate

Graham Formula

Earnings Per Share
EPS Growth (7-10 years)
Government Bond Rate

TTM Financials

Income (TTM)

RevenueGrossNet
Revenue$58.13(B)
Gross profit$48.40(B)
EBITDA$20.42(B)
Net income$9.40(B)
Gross margin83.3%
Operating margin22.0%
Net margin16.2%
Shares outstanding3.10(B)

Balance sheet

Cash & ST inv.Other ST assetsLong term assetsCurrent liabilitiesLong term debtOther LT liabilitiesEquity
Total assets$114.46(B)
Current assets$29.94(B)
Total liabilities$68.48(B)
Current liabilities$34.05(B)
Cash & Short-term inv.$8.18(B)
Long-term debt$24.70(B)
Total intangibles$59.41(B)
PP&E$13.78(B)

Cash flow (TTM)

CFOCFICFF
FCF$12.66(B)
CapEx$-2.48(B)
Dividends paid$-4.97(B)
Stock issued$40.00(M)
Stock repurchased$-508.00(M)
Stock-based comp.$660.00(M)
Debt issued$819.00(M)
Debt repaid$-412.00(M)

Per share data (TTM)

Price: $89.1
Revenue: $18.8 (4.7x | 21.1%) Gross profit: $15.6 (5.7x | 17.5%) Earnings: $3.03 (29.4x | 3.4%)
FCF: $4.08 (21.8x | 4.6%) Stock-based Comp.: $0.21 (418.5x | 0.2%) CapEx.: $0.80 (111.3x | 0.9%) Dividend: $1.57 (56.9x | 1.8%)
Total Assets: $36.9 (2.4x | 41.4%) Total Liabilities: $22.1 (4.0x | 24.8%) Book Value: $14.8 (6.0x | 16.6%) Cash & ST inv.: $2.64 (33.8x | 3.0%) Debt: $7.97 (11.2x | 8.9%)
Earnings FY+1: $4.61 (19.3x | 5.2%) Earnings FY+2: $5.24 (17.0x | 5.9%) Earnings FY+3: $5.87 (15.2x | 6.6%) Earnings FY+4: $6.41 (13.9x | 7.2%) Earnings FY+5: $7.18 (12.4x | 8.1%)
FCF FY+1: $2.91 (30.6x | 3.3%) FCF FY+2: $4.21 (21.1x | 4.7%) FCF FY+3: $4.78 (18.6x | 5.4%) FCF FY+4: $5.21 (17.1x | 5.8%) FCF FY+5: $5.97 (14.9x | 6.7%)

Summary

Growth Estimates

Revenue

CAGR: 6.3%
FY+1FY+2FY+3FY+4FY+5
FY+1$58.72(B)
FY+2(+6.3%)$62.45(B)
FY+3(+6.2%)$66.33(B)
FY+4(+5.7%)$70.09(B)
FY+5(+7.0%)$75.02(B)

Net Income

CAGR: 11.9%
FY+1FY+2FY+3FY+4FY+5
FY+1$14.15(B)
FY+2(+13.6%)$16.08(B)
FY+3(+12.7%)$18.13(B)
FY+4(+10.9%)$20.10(B)
FY+5(+10.6%)$22.22(B)

EPS

CAGR: 11.7%
FY+1FY+2FY+3FY+4FY+5
FY+1$4.61
FY+2(+13.7%)$5.24
FY+3(+12.0%)$5.87
FY+4(+9.2%)$6.41
FY+5(+11.9%)$7.18

FCF per share

CAGR: 19.7%
FY+1FY+2FY+3FY+4FY+5
FY+1$2.91
FY+2(+44.9%)$4.21
FY+3(+13.5%)$4.78
FY+4(+8.9%)$5.21
FY+5(+14.7%)$5.97

Historical Financials

Showing limited histrical data.
TTM (Y)TTM (Q)FYFQ
Income(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.010.0(B)20.0(B)30.0(B)40.0(B)50.0(B)
Revenue Operating Income Net IncomeCOGSGross ProfitTotal OpEx.R&DSG&AInterest ExpenseInterest IncomeOther Non-operating IncomePre-tax incomeIncome tax
Cash flow(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.02.0(B)4.0(B)6.0(B)8.0(B)10.0(B)12.0(B)
Stock-based Comp. FCFCFONet IncomeD&AChange in Working CapitalCFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures
Balance sheet(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.020.0(B)40.0(B)60.0(B)80.0(B)100.0(B)
Total Assets Total LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EIntangible AssetsGoodwillCurrent liabilitiesShort-Term DebtAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity
Per share data(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.01.02.03.04.0
EPS (Basic) FCF/Share Dividend/ShareEPS (Diluted)Book value/ShareCash & ST inv./ShareDebt/Share
Ratios(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.020.040.060.080.0100.0
P/E P/S EV/EarningsP/FCFP/BEV/FCFDebt/EquityPayout ratio
Margins(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0%20%40%60%80%
Net Income Margin Operating Margin Gross MarginEBITDA MarginFCF Margin
Returns(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0%2%4%6%8%10%
ROIC ROAROCEROE
Shares outstanding(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.0500.0(M)1.0(B)1.5(B)2.0(B)2.5(B)3.0(B)
Shares (Basic)Shares (Diluted)
Market Cap.(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.050.0(B)100.0(B)150.0(B)200.0(B)
Market Cap.

AZN vs Peers

Similar Companies

Ownership

Major holders

*Excludes indirect insider ownership

Insiders: 0.00%
Institutions: 16.71%
Other: 83.29%

Institutional ownership

1.98% Price (T.Rowe) Associa...1.52% Primecap Management Co...1.31% Wellington Management ...1.19% Bank of America Corpor...0.95% Capital International ...0.83% FMR, LLC0.81% Fisher Asset Managemen...0.75% Franklin Resources, In...0.54% Sanders Capital, LLC0.47% Morgan Stanley6.36% Others

Trading Summary

In the past year, insiders have bought $291253 worth of the company's stock, and sold $0.00.

Congress members have bought between $2002 - $30000 worth of the company's stock, and sold between $1001 - $15000.

Insider transactions

$0.002025-12$0.00
$0.002025-11$0.00
$0.002025-10$0.00
$0.002025-09$729.00
$0.002025-08$0.00
$0.002025-07$0.00
$0.002025-06$0.00
$0.002025-05$0.00
$0.002025-04$100324
$0.002025-03$0.00
$0.002025-02$0.00
$0.002025-01$0.00
$0.002024-12$0.00
DateSharesTotal ($)Price ($)NameTitle
Buy2025-09-09972981.0Knudsen (Karen)
Buy2025-04-301,400100,32471.7Knudsen (Karen)
Buy2024-11-193,000190,20063.4Mok (Tony)

Congressional trading

$0.002025-12$0.00
$0.002025-11$0.00
$0.002025-10$0.00
$0.002025-09$0.00
$0.002025-08$0.00
$0.002025-07$0.00
$0.002025-06$0.00
$0.002025-05$0.00
$80012025-04$0.00
$0.002025-03$16001
$0.002025-02$0.00
$0.002025-01$0.00
$0.002024-12$0.00
DatePoliticianPartyChamberAmount ($)
Sell2025-04-21Bruce WestermanRHouse$1,001 - $15,000
Buy2025-03-03Bruce WestermanRHouse$1,001 - $15,000
Buy2025-03-03Bruce WestermanRHouse$1,001 - $15,000

Tools

Dividend Income

Investment Amount
Dividend Yield
What is the Dividend Income Calculator?

The Dividend Income Calculator helps you estimate the yearly, quarterly, monthly, and daily income of your investments.

How to Use This Calculator?

Enter the dividend yield and the invested amount. Optionally, preload stock data to automatically fetch the dividend yield.

Required Investment

Dividend Yield
Desired Yearly Payout
Desired Quarterly Payout
Desired Monthly Payout
What is the Required Investment Calculator?

The Required Investment Calculator helps you determine the amount of money you need to invest in a stock to achieve a desired dividend.

How to Use This Calculator?

Enter the dividend yield and your desired dividend income. Optionally, preload stock data to automatically fetch the dividend yield.

Future Dividend Yield

Base Dividend
Current Price
Number of Years
Dividend Growth Rate
What is the Future Yield Calculator?

The Future Yield Calculator helps you estimate the future dividend yield of a stock based on its current dividend, price, and expected dividend growth rate.

How to Use This Calculator?

Enter the base dividend, current price, number of years, and dividend growth rate. Optionally, preload stock data to automatically fetch the dividend and price. The calculator will display the current yield and the projected future yield.

Future Dividend Income

Base Dividend
Number of Years
Dividend Growth Rate
What is the Future Dividend Income Calculator?

The Future Dividend Income Calculator helps you estimate the future dividend income from your investments based on the current dividend yield and expected growth rate.

How to Use This Calculator?

Enter the current dividend yield, expected growth rate, and investment duration. Optionally, preload stock data to automatically fetch the dividend yield.